NEW YORK, Nov. 27 - Gentris, a clinical pharmacogenomics testing and diagnostic products company, and MDS Pharma Services will partner to establish a genomic database of genotyped volunteers and diagnostic reference controls, the firms said on Tuesday.
Terms of the agreement call for Gentris to genotype individuals for genes associated with drug metabolism for MDS' gene library. In return, Gentris will gain access to the library, whose samples "will be immediately commercialized" by Gentris and an undisclosed number of collaborators as pharmacogenomic diagnostics.
Financial details of the agreement were not disclosed.
"Governmental agencies and the drug development community believe that new quality and regulatory standards will be implemented in the near term," said Michael P. Murphy, president and CEO of Research Triangle Park, NC-based Gentris. Gentris has "the ultimate goal of becoming a diagnostic product developer of high quality, standardized solutions for clinical pharmacogenomic laboratories."
From MDS' perspective, the agreement allows the company "to provide genetically profiled volunteers for clinical trials we conduct for our customers," said Jerry Merritt, senior vice president for early clinical research at MDS Pharma.